T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Colorectal Cancer
Interventions
BIOLOGICAL

Adaptive autologous cell immunotherapy

each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.

Trial Locations (1)

75013

Service hépato-gastro-enterologie, Pitié-Salpêtrière Hospital, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT00986518 - T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study | Biotech Hunter | Biotech Hunter